<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995120</url>
  </required_header>
  <id_info>
    <org_study_id>Larynx-IO 1.0</org_study_id>
    <secondary_id>2103232-1</secondary_id>
    <nct_id>NCT04995120</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma</brief_title>
  <acronym>INSIGHT</acronym>
  <official_title>Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to define whether combination of induction chemotherapy and PD-1&#xD;
      inhibitor (Toripalimab) improve the rate of larynx preservation, for patients with resectable&#xD;
      laryngeal/hypopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Historically, induction chemotherapy could provide a chance of larynx preservation for&#xD;
      approximate 60-70% of patients with locally advanced laryngeal/hypopharyngeal carcinoma.&#xD;
      Recently, phase I-II clinical studies demonstrated excellent pathological response of&#xD;
      induction PD-1 inhibitor with/without chemotherapy for locally advanced head and neck cancer.&#xD;
      The aim of this study is to define whether combination of induction chemotherapy and PD-1&#xD;
      inhibitor (Toripalimab) improve the rate of larynx preservation, for patients with resectable&#xD;
      laryngeal/hypopharyngeal carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laryngeal Preservation rate at 3-month post-radiotherapy</measure>
    <time_frame>3-month post-radiotherapy</time_frame>
    <description>defined as the absence of any residual disease that would justify salvage total laryngectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate of induction therapy</measure>
    <time_frame>2 weeks after the 3th cycle of induction therapy</time_frame>
    <description>Overall response rate of induction therapy evaluated by head and neck MR/CT, laryngoscopy using Recist 1.1 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate of the patients receiving surgical resection</measure>
    <time_frame>Within 3 weeks after surgery</time_frame>
    <description>Pathological complete response rate of the patients receiving surgical resection, evaluated by experienced pathologists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major pathologic response rate of the patients receiving surgical resection</measure>
    <time_frame>Within 3 weeks after surgery</time_frame>
    <description>Major pathologic response rate, defined as no more than 10% of residual viable tumor, evaluated by experienced pathologists.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate at 1 year</measure>
    <time_frame>One year post-radiotherapy</time_frame>
    <description>Overall survival rate at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate at 1 year</measure>
    <time_frame>One year post-radiotherapy</time_frame>
    <description>Progression-free survival rate at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laryngeal Preservation rate at 1 year</measure>
    <time_frame>One year post-radiotherapy</time_frame>
    <description>Laryngeal Preservation rate at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect</measure>
    <time_frame>One year post-radiotherapy</time_frame>
    <description>Adverse Effect, evaluated by CTCAE 4.0.03</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Laryngeal Preservation rate at 3 month post-radiotherapy by different biomarker subgroups</measure>
    <time_frame>3-month post-radiotherapy</time_frame>
    <description>Experimental Biomarker Analysis: the relationship with different biomarkers and 3 month laryngeal preservation rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall response rate of induction therapy, by different biomarker subgroups</measure>
    <time_frame>2 weeks after the 3th cycle of induction therapy</time_frame>
    <description>Experimental Biomarker Analysis: the relationship with different biomarkers and overall response rate of induction therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Pathological complete response rate by different biomarker subgroups</measure>
    <time_frame>Within 3 weeks after surgery</time_frame>
    <description>Experimental Biomarker Analysis: the relationship with different biomarkers and pathological complete response rate of the patients receiving surgical resection</description>
  </other_outcome>
  <other_outcome>
    <measure>Major pathologic response rate by different biomarker subgroups</measure>
    <time_frame>Within 3 weeks after surgery</time_frame>
    <description>Experimental Biomarker Analysis: the relationship with different biomarkers and major pathologic response rate of the patients receiving surgical resection</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Laryngeal Cancer</condition>
  <condition>Hypopharynx Cancer</condition>
  <condition>Laryngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Induction chemotherapy and Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.&#xD;
Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If ORR of primary tumor is CR/PR, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 1year. Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 1year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy TP regimen combined with Toripalimab</intervention_name>
    <description>Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.&#xD;
Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 1year. Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 1year.</description>
    <arm_group_label>Induction chemotherapy and Toripalimab</arm_group_label>
    <other_name>Paclitaxel or Nab-Paclitaxel</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed, resectable locally advanced laryngeal/hypopharyngeal&#xD;
             squamous cell carcinoma (T2-4a, N0-resectable N3, M0);&#xD;
&#xD;
          -  Age between 18-75 years;&#xD;
&#xD;
          -  Signed inform consent;&#xD;
&#xD;
          -  Had at least one measurable lesion according to RECIST 1.1 criteria&#xD;
&#xD;
          -  Anticipated overall survival more than 3 months;&#xD;
&#xD;
          -  Satisfactory performance status: ECOG (Eastern Cooperative Oncology Group) scale 0-1;&#xD;
&#xD;
          -  Normal organ function;&#xD;
&#xD;
          -  HBV DNA&lt;500 IU/mL（or 2500 copies/mL）and HCV RNA negative ;&#xD;
&#xD;
          -  Male and no pregnant female, able to adapt birth control methods during treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to Toripalimab, Paclitaxel, Nab-Paclitaxel and Cisplatin;&#xD;
&#xD;
          -  Suffered from malignant tumors, except cervical carcinoma in situ, papillary thyroid&#xD;
             carcinoma, or skin cancer (non- melanoma) within five years;&#xD;
&#xD;
          -  Severe, uncontrolled heart disease;&#xD;
&#xD;
          -  Receive vaccine or live vaccine within 28 days prior to signing the informed consent;&#xD;
&#xD;
          -  Equivalent dose more than prednisone 10mg/d or other immunosuppressive treatments&#xD;
             within 28 days prior to signing the informed consent;&#xD;
&#xD;
          -  Surgery or trauma within 28 days prior to signing the informed consent;&#xD;
&#xD;
          -  Received other immune checkpoint inhibitors previously;&#xD;
&#xD;
          -  Severe, uncontrolled infections within 28 days of prior to signing the informed&#xD;
             consent;&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease; Type I Diabetes, hypothyroidism those&#xD;
             only need hormone replacement therapy, vitiligo or inactive asthma who don't need&#xD;
             systemic therapy can recruit;&#xD;
&#xD;
          -  History of interstitial lung disease;&#xD;
&#xD;
          -  HIV positive;&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAg) positive and HBV-DNA ≥500IU/ml, or 2500cps/ml;&#xD;
             Positive HCV RNA;&#xD;
&#xD;
          -  Other diseases which may influence the safety or compliance of the clinical trial,&#xD;
             such as mental illness, or their family and society factors;&#xD;
&#xD;
          -  Women of child-bearing potential who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiayun He, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan Universtiy Shanghai Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan Universtiy Shanghai Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiayun He, M.D.</last_name>
    <phone>(86)021-64175590</phone>
    <phone_ext>81400</phone_ext>
    <email>hexiayun1962@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Wang, M.D.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiayun He, MD</last_name>
      <phone>+86-18017312167</phone>
      <email>hexiayun1962@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaomin Ou, MD</last_name>
      <phone>+86-18017317872</phone>
      <email>0456218@fudan.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation. J Natl Cancer Inst. 2015 Dec 16;108(4). pii: djv368. doi: 10.1093/jnci/djv368. Print 2016 Apr.</citation>
    <PMID>26681800</PMID>
  </reference>
  <reference>
    <citation>Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991 Jun 13;324(24):1685-90.</citation>
    <PMID>2034244</PMID>
  </reference>
  <reference>
    <citation>Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 1;31(7):845-52. doi: 10.1200/JCO.2012.43.6097. Epub 2012 Nov 26.</citation>
    <PMID>23182993</PMID>
  </reference>
  <reference>
    <citation>Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013 Mar 1;31(7):853-9. doi: 10.1200/JCO.2012.42.3988. Epub 2013 Jan 22. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702.</citation>
    <PMID>23341517</PMID>
  </reference>
  <reference>
    <citation>Weiss J, Gilbert J, Deal AM, Weissler M, Hilliard C, Chera B, Murphy B, Hackman T, Liao JJ, Grilley Olson J, Hayes DN. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. Oral Oncol. 2018 Sep;84:46-51. doi: 10.1016/j.oraloncology.2018.06.028. Epub 2018 Jul 19.</citation>
    <PMID>30115475</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiayun He, MD</investigator_full_name>
    <investigator_title>M.D., professor</investigator_title>
  </responsible_party>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Checkpoint inhibitor</keyword>
  <keyword>PD-1 inhibitor</keyword>
  <keyword>Toripalimab</keyword>
  <keyword>Larynx preservation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

